The Wolverine Blend

Why people stack vs single-peptide

Animal evidence suggests the two together heal soft tissue faster than either alone, especially for connective-tissue injuries - tendons (the cords connecting muscle to bone) and ligaments (the cords connecting bone to bone) - and gut-wall damage. The word "faster" in animal models does not guarantee "faster" in humans, but it is the rationale behind the stack.

Most protocol writers and sports-medicine doctors who prescribe peptides will offer either single BPC-157 or the blend, depending on injury severity. The blend carries two tradeoffs worth naming upfront: it costs more because you are buying two peptides instead of one, and the human safety data is thinner than for BPC-157 alone.

Who this is for - and who it is not for

For: someone who ran single BPC-157 for four weeks with limited improvement, with a sports-medicine doctor's go-ahead to escalate. Or someone with a serious soft-tissue injury where a sports-medicine doctor recommends the stack from week one rather than starting single-peptide.

Not for: anyone with an active or recent cancer history, pregnancy, or who is on blood thinners without explicit doctor approval. These are the same exclusions that apply to single BPC-157.

One additional exclusion that does not apply to single BPC-157: TB-500 is banned by WADA (the World Anti-Doping Agency, which sets drug-testing rules for Olympic and professional sport competitions). If you compete at any level where WADA rules apply, do not use this stack. Full stop.

Week 0: the doctor conversation

The same three questions from the BPC-157 protocol apply here, adjusted for the stack:

• Are you familiar with the Wolverine stack specifically? Not just BPC-157 in general. The doctor should know what TB-500 is and why someone would add it.
• Which compounding pharmacy do you use, and do they provide a COA (Certificate of Analysis - the lab report proving the bottle contains what the label says) per peptide? Not one shared COA for both. One per peptide.
• Would you script a 4-week trial? If they say single BPC-157 first, that is the right answer in most cases. Ask why the injury warrants both peptides before agreeing to the stack.

Many sports-medicine doctors will push back and recommend the single-peptide route. That is not a bad outcome - it is the correct answer for most soft-tissue injuries. The stack is the escalation path, not the default.

Week 1: sourcing - this is where the blend gets dangerous

The Wolverine blend is not more dangerous than single BPC-157 in terms of the peptides themselves. It is more dangerous in terms of sourcing risk, because vendors selling pre-mixed blends introduce contamination and dose imprecision that single-peptide vials avoid.

The sourcing rules:

• Compounding pharmacy via telehealth, with a separate COA for each peptide. The blend can arrive as two separate vials (preferred) or one combined vial, but only if the pharmacy provides a COA per peptide before mixing. No COA, no buy.
• If using a research peptide vendor: single-peptide bottles only, with a COA per peptide. Mix at injection time yourself. This minimizes the dose imprecision that comes from pre-mixed blends.
• Skip: pre-mixed "Wolverine blend" bottles from research vendors with one COA covering both peptides. The mixing process is where contamination enters and dose precision exits.
• Storage: refrigerated at 36-46 degrees F. Reconstitute (mix) with bacteriostatic water (water with a small amount of benzyl alcohol added to prevent bacterial growth) at injection time, not in advance.

Weeks 2-5: the 4-week stack protocol

Run both peptides in parallel on the following schedule:

• BPC-157: inject 250mcg subQ (subcutaneously - just under the skin, not into muscle) twice daily, targeting a site near the injury. Standard injection technique applies: pinch, angle, slow plunge.
• TB-500: inject 2mg subQ twice weekly (Monday and Thursday), at a separate site from the BPC-157 injection. Different site matters - you are tracking which injection correlates with which response.
• Log every dose, site, and pain score (0-10) daily. This is not optional. Without a log you cannot tell the stack from placebo or track what is working.
• Keep up PT (physical therapy) and activity modification. The stack is a complement to movement-based rehab, not a replacement for it. Tendons need mechanical load to remodel. Rest alone plus peptides is not the protocol.
• Reassess at 14 days. Zero improvement in pain score or activity tolerance at day 14 is a signal the stack probably is not working for this specific injury. Have the follow-up conversation before continuing.
• Stop at week 4. Longer is not better. The evidence base does not support extended runs, and the risk-benefit calculation shifts once you are past the treatment window.

What success looks like

The milestones parallel the single BPC-157 protocol but on a slightly faster trajectory, based on what animal models and practitioner reports suggest:

• Days 10-12: meaningful drop in resting pain score. Not zero, but a measurable shift in the wrong-direction trend.
• Day 21: improved activity tolerance. You can do things at week three that were too painful at week one.
• End of week 4: injury is either resolved or manageable enough to continue standard rehab without the stack.

If neither of the first two checkpoints land, stop and have the follow-up conversation with your doctor. The stack failing is data. Continuing past a clear non-response is not.

What to skip

• Pre-mixed Wolverine blend bottles from gym-bro vendors with one shared COA. This is the failure mode. Not the blend itself - the sourcing shortcut.
• "Five-peptide healing stacks" that combine BPC-157, TB-500, IGF-1 (Insulin-like Growth Factor 1), MGF (Mechano Growth Factor), and GHK-Cu (a copper peptide) in one vial. The Wolverine stack is two peptides because that is where the biological evidence lives. More peptides per vial means more surface area for imprecision and less ability to attribute results.
• Doses above the protocol amounts without a doctor's instruction. Higher doses are not validated and add zero proven benefit at this evidence level.
• Self-tapering or extending past week 4. The protocol ends at four weeks. Tapering is not supported by the evidence. Extending is not supported by the evidence.

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.

Subscribe free